Human Immunodeficiency Virus Mutations during the
http://www.100md.com
病菌学杂志 2005年第17期
Blood Systems Research Institute, San Francisco, California 94118
Department of Medicine, University of California, San Francisco, California 94118
Department of Surgery, University of California, San Francisco, California 94143
Grifols Biologicals, Los Angeles, California 90032
ABSTRACT
The full protein coding region of human immunodeficiency virus (HIV) genomes were sequenced using plasma collected from nine African-Americans prior to seroconversion and 7 to 28 days later. HIV mutations emerged in seven of these subjects at a genomewide rate of 2% per year. The location of nonsynonymous (NS) HIV mutations within these subjects was compared to their potential HLA-A and B types restricted CTL epitopes reported in the Los Alamos National Laboratory HIV immunology database. A statistically significant (P < 0.005) number of the early NS mutations (13.5%) were found within previously reported CTL epitopes. A virus sequencing and reported CTL epitopes database analysis therefore support a model where a significant proportion of very early nonsynonymous HIV mutations are selected by CTL.
TEXT
Cytotoxic T-lymphocytes (CTL) play an important role in controlling viremia during primary human immunodeficiency virus (HIV) infection (6, 29). CTL recognize viral peptides presented in a complex with HLA class I molecules at the surface of infected cells, inducing T-cell activation and clonal expansions followed by lysis of infected target cells (37, 40). The resulting selection pressure on the replicating virus can lead to the emergence of CTL escape variants (7, 9, 18-20, 22, 25, 26, 36). CTL targeted epitopes have been reported in every HIV protein in the Los Alamos Database (28). The breadth of HIV-1-specific CTL response increases during chronic versus primary infection (4, 8, 13, 19). CTL responses appear to favor epitopes within regulatory and accessory proteins during primary infection, whereas later responses appear to preferentially recognize structural proteins (1, 8, 9).
CTL escape has been powerfully illustrated by the identification of an immunodominant Mamu-A01-restricted Tat-specific CTL response rapidly selecting for viral escape variants during acute simian immunodeficiency virus (SIV) infection (3, 32). In the SIV model system, peptide reagents of the infecting SIV strain have allowed all CTL epitopes restricted by various HLA class I allele to be identified. As many as 64% of NS mutations selected over the entire course of SIV infection outside of the envelope gene have been located with known CTL epitopes (33). In HIV-1-infected subjects, viral mutations preventing CTL recognition were described in immunodominant epitopes and were correlated with a steady rise in viral load and disease progression (18, 25).
On a population basis, Moore et al. compared HIV protease and reverse transcriptase sequences of chronically infected patients to their presumably ancestral subtype consensus sequence and showed that consensus deviating sequences were overrepresented in known HLA-restricted CTL epitopes (31). When phylogenetically closely related but epidemiologically unlinked HIV genomes were analyzed positive selection in potential CTL target sites was also detected (35). Particular HLA types have also been associated with susceptibility or resistance to HIV infection (14, 30, 38) as well as with slow or rapid disease progression (10, 11, 16, 17, 21, 23, 24, 39).
To directly identify HIV sequence changes and characterize HIV-1 regions undergoing possible selection very early following infection, we sequenced plasma HIV genomes of nine African-American plasma donors at two time points (Fig. 1). Subjects reported no symptoms of acute infection at the time of plasma collection and were not febrile. The initial donations were p24 antigen negative, anti-HIV-1 antibody negative, and HIV-1 RNA negative (using the National Genetics Institute UltraQual HIV-1 reverse transcription-PCR assay with a detection limit of five HIV-1 genome copies/ml) except for subjects 1057 and PRB959, who had an initial plasma viremia of 3.9 x 104 and 2 x 105 HIV-1 RNA copies/ml, respectively (Fig. 1). Longitudinally collected plasma samples were then quantified with the NGI SuperQuant HIV-1 reverse transcription-PCR assay. Anti-HIV antibodies were detected using the HIV-1 enzyme immunoassay (Abbott, Abbott Park, IL) and p24 antigenemia was detected with the Coulter HIV-1 p24 antigen assay (Beckman Coulter, Brea, CA) (Fig. 1). Antiretroviral therapies were not initiated during the period of study. Because donations were of plasma only, no peripheral blood mononuclear cells were available for functional analyses of the CTL response. These studies were approved by the University of California, San Francisco Committee on Human Research.
Seroconversion was observed during the second or third week following initial RNA detection for seven subjects, during week 1 for 1001, and during the fourth week for 1057. The initial plasma donations of subject 1057 and PRB959 were already viremic but subsequent seroconversion confirmed primary infection status.
All open reading frames of plasma HIV-1 RNA from two time points separated by 7 to 28 days (arrows in Fig. 1) were sequenced. For genome amplification plasma HIV-1 RNA was purified, reverse transcribed, and subjected to nested PCR (5). The resulting half-genome amplicons were directly sequenced. The PCR and sequencing protocols have been described in detail (5). Sequences were manually edited using EditView, assembled into a single contig, and aligned using the Seqman and Megalign programs, respectively (DNAstar Inc., Madison, WI). The wide variation in the location of HIV mutations evolving within each subject is shown in Fig. 2.
Both complete and partial nucleotide sequence changes were observed by direct amplicon sequencing. Partial nucleotide changes were detected when either time point showed a mixed base consisting of two overlapping sequencing electrophoregram peaks (where the minority peak reached 25% of the dominant peak) while the other time point showed only a single base peak. These mixed bases are recorded using the IUB nomenclature in the deposited sequences (GenBank accession numbers AY331282 to AY331297, AY332236, and AY332237). Mixed bases, commonly seen when directly sequencing HIV amplicons, reflect polymorphisms in the viral quasispecies that are not yet fixed in the entire viral population. The short time interval between sampled plasma pairs is likely responsible for the frequent detection of such partial nucleotide changes. Partial mutations were analyzed in the same way as full nucleotide substitutions (i.e., positions changing from single into mixed residues, and vice versa, were counted as one mutation). No codon contained more than a single mixed base, and therefore all codons with a mixed base could be translated into only one or two amino acids.
No mutations were observed in subjects 1006 and 1027, who were sampled only 7 and 12 days apart (Fig. 1). For the seven other genome pairs, a total of 107 nucleotide substitutions were detected, resulting in intrasubject mutation frequencies of 0.08% to 0.37%. The accumulation of nucleotide substitutions occurred at an average yearly rate of 2.05%. The genomewide dN/dS ratios, calculated using the SNAP program from the HIV sequence database [www.hiv.lanl.gov (27)], ranged from 0.249 to 0.87, reflecting overall purifying selection against amino acid changes. The gene distribution of NS mutations varied widely between donors. Overall the highest number of NS mutations was located in env (n = 19), pol (n = 15), gag (n = 14), nef (n = 6), vif (n = 3), and vpr (n = 3). In these subjects no NS mutations were detected in the early expressed accessory genes tat, rev, and vpu. When adjusted for gene length, the highest density of NS mutations was found with the vpr, nef, and gag genes (The high mutation rate for the short open reading frame of vpr was the result of a single NS mutation in three subjects [1013, 1018, and 1057] located within Vpr amino acids 34 to 40).
The total number of nucleotide substitutions was correlated with both the time interval between the two sequenced time points and the time interval between the initial detection of HIV RNA and the second sequenced time point (P = 0.05, r2 = 0.32 and P = 0.02, r2 = 0.48, respectively). The number of nucleotide substitutions was also positively correlated with changes in plasma viremia between the two sequenced time points (P = 0.04, r2 = 0.37) indicating that increasing viral loads were associated with a higher number of mutations. Similar trends were observed using NS mutations only (P = 0.09, r2 = 0.24; P = 0.006, r2 = 0.62; and P = 0.06, r2 = 0.3, respectively).
HIV-1 evolution is influenced by numerous virus-host interactions including changes in antibody and CTL selection pressures upon infection of a new host. In order to evaluate the influence of the HLA class I types on the location of early NS mutations, high-resolution HLA-A and -B types were determined by PCR and sequencing of human DNA purified from plasma samples. DNA was isolated in a clean room designed for pre-PCR manipulation using the QIAamp DNA mini kit (QIAGEN, Valencia, CA). Locus-specific PCR amplifications were performed for exons 2 and 3; exon 4 was amplified as required to resolve ambiguities (Perkin Elmer Life Sciences, Shelton, CT) (L. A. Baxter-Lowe, unpublished). Ambiguities involving polymorphism in the leader peptide (HLA-A7401/02 and B2705/13) were not resolved, because these mutations are not predicted to alter the peptide binding characteristics of the protein product. These are listed in Table 1 as HLA-A7401 and HLA-B2705. For subject 1013, there was insufficient DNA to resolve the exon 4 ambiguity of HLA-A2301/07N. This has been listed in Table 1 as HLA-A2301 as HLA-A2307N is extremely rare. Eighteen different HLA-A and -B types were detected among the seven plasma donors whose HIV evolved between the sampled time points (Table 1). Many of these types are frequently observed in African-Americans (10).
When published CTL epitopes for these 18 HLA class I molecules were sought in the existing literature only 13 of 18 HLA types had any CTL epitopes described (Los Alamos HIV immunology database, January 2005). A total of 62 HIV CTL epitopes with a range of 1 to 16 underlined epitopes per HLA type were identified. Eight of the 59 HIV NS mutations (13.5%) were located within reported HLA class I restricted epitopes (Table 2). These eight NS mutations, found in three subjects, were within epitopes restricted by one or in two cases by two of their host's class I molecules (Table 2).
We calculated the probability of 8 out of 59 NS mutations occurring within previously reported CTL epitopes for the seven subjects with HIV mutations. All 62 reported epitopes restricted by their hosts' class I HLA-A and HLA-B molecules were compiled from the database. The total numbers of amino acids included within reported CTL epitopes were calculated individually for each of the seven primary infection subjects and then added up (the same amino acids found in overlapping epitopes within the same subject were counted once). A total of 943 amino acids were found within reported CTL epitopes. The total number of amino acids encoded by HIV in these seven subjects was 22,048 (Table 3). The fraction of virally encoded amino acids within reported CTL epitopes was therefore 943/22,048 (4.3%). The proportion of NS mutations found within these reported CTL epitopes was 8/59 (13%), which was significantly greater than expected by chance, considering the low density (4.3%) of reported CTL epitopes (P < 0.005, test of proportion and Fisher’s exact test). This result indicated that NS mutations evolving within the first month of infection were significantly more likely to be found within than outside a reported CTL epitope.
We also calculated separately for each subject and for all subjects together the odds ratio of finding an NS mutation in a predicted CTL epitope (Table 3). Odds ratio values in three subjects were greater than one, ranging from 3.9 to 5.7, reflecting the preferential location of NS mutations within reported CTL epitopes. An odds ratio of 3.1 was calculated using all seven subjects with HIV mutations.
The number of CTL epitopes restricted by the HLA class I molecules of these African American plasma donors in the Los Alamos databases is likely to be a large underestimate of potential epitopes, because many of these HLA types have not been studied in detail (i.e., no CTL epitopes were reported for 5 of the 18 HLA types). Furthermore most studies mapping epitopes have done so using only a subset of HIV proteins, and epitopes have typically been identified using reference or subtype consensus strains rather than autologous strains. Mutational escape from CTL can also occur at different steps during peptide processing and HLA binding. Viral protein degradation by the proteasome, transport of peptides into the endoplasmic reticulum, peptide trimming, and peptide loading may all be affected by sequence changes flanking rather than within the final antigenic peptide (2, 12, 15). Finally, some NS mutations linearly distant from the CTL epitope may also be selected as compensatory mutations to reduce the fitness cost imposed by CTL escape mutations (34).
The immature state of the immune response so early following primary infection may also have limited the amount of CTL selection pressure on the replicating quasispecies although in the SIV model system immunodominant epitope escape mutations have been seen within 4 weeks of infection (3, 32). The percentage of early NS mutations reported here that may affect CTL epitopes may therefore be a minimum value. Indeed we noted that the two subjects with the highest number of HLA-A and -B types restricted CTL epitopes in the database (1001 and 1057) were among the three subjects with an overabundance of NS mutations within reported epitopes (Tables 2 and 3). As more CTL epitopes to less frequent HLA-A and -B types are reported, a greater proportion of very early NS mutations may therefore be found within CTL epitopes.
In summary, the location of NS mutations occurring within the first month of acute HIV infection varied greatly among subjects. The influence of the host's class I HLA type was reflected within weeks of infection by the preferential distribution of 13.5% of NS mutations within previously reported CTL epitopes.
ACKNOWLEDGMENTS
Support for this study was provided to E.L.D. by the UC Universitywide AIDS Research Program (ID02-SF-075) and NIAID (AI47320 and AI43261).
REFERENCES
Addo, M. M., M. Altfeld, E. S. Rosenberg, R. L. Eldridge, M. N. Philips, K. Habeeb, A. Khatri, C. Brander, G. K. Robbins, G. P. Mazzara, P. J. Goulder, and B. D. Walker. 2001. The HIV-1 regulatory proteins Tat and Rev. are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. USA 98:1781-1786.
Allen, T. M., M. Altfeld, X. G. Yu, K. M. O'Sullivan, M. Lichterfeld, S. Le Gall, M. John, B. R. Mothe, P. K. Lee, E. T. Kalife, D. E. Cohen, K. A. Freedberg, D. A. Strick, M. N. Johnston, A. Sette, E. S. Rosenberg, S. A. Mallal, P. J. Goulder, C. Brander, and B. D. Walker. 2004. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78:7069-7078.
Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386-390.
Altfeld, M., E. S. Rosenberg, R. Shankarappa, J. S. Mukherjee, F. M. Hecht, R. L. Eldridge, M. M. Addo, S. H. Poon, M. N. Phillips, G. K. Robbins, P. E. Sax, S. Boswell, J. O. Kahn, C. Brander, P. J. Goulder, J. A. Levy, J. I. Mullins, and B. D. Walker. 2001. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193:169-180.
Bernardin, F., B. L. Herring, L. Peddada, and E. L. Delwart. 2003. Primary infection of a male plasma donor with divergent HIV variants from the same source followed by rapid fluctuations in their relative frequency and viral recombination. AIDS Res. Hum. Retroviruses 19:1009-1015.
Borrow, P., H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. Oldstone. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
Cao, J., J. McNevin, S. Holte, L. Fink, L. Corey, and M. J. McElrath. 2003. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J. Virol. 77:6867-6878.
Cao, J., J. McNevin, U. Malhotra, and M. J. McElrath. 2003. Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J. Immunol. 171:3837-3846.
Carrington, M., and R. E. Bontrop. 2002. Effects of MHC class I on HIV/SIV disease in primates. AIDS 16(Suppl. 4):S105-114.
Carrington, M., G. W. Nelson, M. P. Martin, T. Kissner, D. Vlahov, J. J. Goedert, R. Kaslow, S. Buchbinder, K. Hoots, and S. J. O'Brien. 1999. HLA and HIV-1: heterozygote advantage and B35-Cw04 disadvantage. Science 283:1748-1752.
Craiu, A., T. Akopian, A. Goldberg, and K. L. Rock. 1997. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc. Natl. Acad. Sci. USA 94:10850-10855.
Dalod, M., M. Dupuis, J. C. Deschemin, C. Goujard, C. Deveau, L. Meyer, N. Ngo, C. Rouzioux, J. G. Guillet, J. F. Delfraissy, M. Sinet, and A. Venet. 1999. Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J. Clin. Investig. 104:1431-1439.
de Sorrentino, A. H., K. Marinic, P. Motta, A. Sorrentino, R. Lopez, and E. Illiovich. 2000. HLA class I alleles associated with susceptibility or resistance to human immunodeficiency virus type 1 infection among a population in Chaco Province, Argentina. J. Infect. Dis. 182:1523-1526.
Draenert, R., S. Le Gall, K. J. Pfafferott, A. J. Leslie, P. Chetty, C. Brander, E. C. Holmes, S. C. Chang, M. E. Feeney, M. M. Addo, L. Ruiz, D. Ramduth, P. Jeena, M. Altfeld, S. Thomas, Y. Tang, C. L. Verrill, C. Dixon, J. G. Prado, P. Kiepiela, J. Martinez-Picado, B. D. Walker, and P. J. Goulder. 2004. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J. Exp. Med. 199:905-915.
Gao, X., G. W. Nelson, P. Karacki, M. P. Martin, J. Phair, R. Kaslow, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, S. J. O'Brien, and M. Carrington. 2001. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344:1668-1675.
Geczy, A. F., H. Kuipers, M. Coolen, L. J. Ashton, C. Kennedy, G. Ng, R. Dodd, R. Wallace, T. Le, C. H. Raynes-Greenow, W. B. Dyer, J. C. Learmont, and J. S. Sullivan. 2000. HLA and other host factors in transfusion-acquired HIV-1 infection. Hum. Immunol. 61:172-176.
Geels, M. J., M. Cornelissen, H. Schuitemaker, K. Anderson, D. Kwa, J. Maas, J. T. Dekker, E. Baan, F. Zorgdrager, R. van den Burg, M. van Beelen, V. V. Lukashov, T. M. Fu, W. A. Paxton, L. van der Hoek, S. A. Dubey, J. W. Shiver, and J. Goudsmit. 2003. Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J. Virol. 77:12430-12440.
Goulder, P. J., C. Brander, Y. Tang, C. Tremblay, R. A. Colbert, M. M. Addo, E. S. Rosenberg, T. Nguyen, R. Allen, A. Trocha, M. Altfeld, S. He, M. Bunce, R. Funkhouser, S. I. Pelton, S. K. Burchett, K. McIntosh, B. T. Korber, and B. D. Walker. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412:334-338.
Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-217.
Hendel, H., S. Caillat-Zucman, H. Lebuanec, M. Carrington, S. O'Brien, J. M. Andrieu, F. Schachter, D. Zagury, J. Rappaport, C. Winkler, G. W. Nelson, and J. F. Zagury. 1999. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 162:6942-6946.
Jones, N. A., X. Wei, D. R. Flower, M. Wong, F. Michor, M. S. Saag, B. H. Hahn, M. A. Nowak, G. M. Shaw, and P. Borrow. 2004. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J. Exp. Med. 200:1243-1256.
Kaslow, R. A., M. Carrington, R. Apple, L. Park, A. Munoz, A. J. Saah, J. J. Goedert, C. Winkler, S. J. O'Brien, C. Rinaldo, R. Detels, W. Blattner, J. Phair, H. Erlich, and D. L. Mann. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-411.
Keet, I. P., J. Tang, M. R. Klein, S. LeBlanc, C. Enger, C. Rivers, R. J. Apple, D. Mann, J. J. Goedert, F. Miedema, and R. A. Kaslow. 1999. Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. J. Infect. Dis. 180:299-309.
Kelleher, A. D., C. Long, E. C. Holmes, R. L. Allen, J. Wilson, C. Conlon, C. Workman, S. Shaunak, K. Olson, P. Goulder, C. Brander, G. Ogg, J. S. Sullivan, W. Dyer, I. Jones, A. J. McMichael, S. Rowland-Jones, and R. E. Phillips. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375-386.
Koenig, S., A. J. Conley, Y. A. Brewah, G. M. Jones, S. Leath, L. J. Boots, V. Davey, G. Pantaleo, J. F. Demarest, C. Carter, et al. 1995. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1:330-336.
Korber, B. HIV signature and sequence variation analysis, p. 55-72. In A. G. Rodrigo and G. H. Learn (ed.), Computational analysis of HIV molecular sequences. Kluwer Academic Publishers, Dordrecht, The Netherlands.
Korber, B. T. M., C. Brander, B. F. Haynes, R. A. Koup, C. Kuiken, J. P. Moore, B. D. Walker, and D. I. Watkins. 2002. HIV molecular immunology, LA-UR 03-5816 ed. Los Alamos National Library Theoretical Biology and Physics, Los Alamos, N.Mex.
Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
MacDonald, K. S., K. R. Fowke, J. Kimani, V. A. Dunand, N. J. Nagelkerke, T. B. Ball, J. Oyugi, E. Njagi, L. K. Gaur, R. C. Brunham, J. Wade, M. A. Luscher, P. Krausa, S. Rowland-Jones, E. Ngugi, J. J. Bwayo, and F. A. Plummer. 2000. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:1581-1589.
Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439-1443.
O'Connor, D. H., T. M. Allen, T. U. Vogel, P. Jing, I. P. DeSouza, E. Dodds, E. J. Dunphy, C. Melsaether, B. Mothe, H. Yamamoto, H. Horton, N. Wilson, A. L. Hughes, and D. I. Watkins. 2002. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:493-499.
O'Connor, D. H., A. B. McDermott, K. C. Krebs, E. J. Dodds, J. E. Miller, E. J. Gonzalez, T. J. Jacoby, L. Yant, H. Piontkivska, R. Pantophlet, D. R. Burton, W. M. Rehrauer, N. Wilson, A. L. Hughes, and D. I. Watkins. 2004. A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J. Virol. 78:14012-14022.
Peyerl, F. W., D. H. Barouch, W. W. Yeh, H. S. Bazick, J. Kunstman, K. J. Kunstman, S. M. Wolinsky, and N. L. Letvin. 2003. Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J. Virol. 77:12572-12578.
Piontkivska, H., and A. L. Hughes. 2004. Between-host evolution of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1: an approach based on phylogenetically independent comparisons. J. Virol. 78:11758-11765.
Price, D. A., P. J. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. Troop, C. R. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94:1890-1895.
Rammensee, H. G., J. Bachman, and S. Stevanovich. 1997. MHC ligands and peptide motifs. Landes Biosciences., Georgetown, Texas.
Rowland-Jones, S. L., T. Dong, K. R. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyoshi, J. Oyugi, E. Ngugi, J. Bwayo, K. S. MacDonald, A. J. McMichael, and F. A. Plummer. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Investig. 102:1758-1765.
Tang, J., C. Costello, I. P. Keet, C. Rivers, S. Leblanc, E. Karita, S. Allen, and R. A. Kaslow. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 15:317-324.
Zinkernagel, R. M., and P. C. Doherty. 1979. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27:51-177.(Flavien Bernardin, Denice)
婵犵數濮烽弫鎼佸磿閹寸姴绶ら柦妯侯棦濞差亝鍋愰悹鍥皺椤︻厼鈹戦悩缁樻锭婵炲眰鍊濋、姘舵焼瀹ュ棛鍘卞┑鐐村灥瀹曨剟寮搁妶鍡愪簻闁冲搫鍟崢鎾煛鐏炲墽鈽夐柍钘夘樀瀹曪繝鎮欏顔介獎闂備礁鎼ˇ顐﹀疾濠婂吘娑㈠礃椤旇壈鎽曞┑鐐村灦鑿ら柡瀣叄閻擃偊宕堕妸锕€鐨戦梺绋款儐閹歌崵绮嬮幒鏂哄亾閿濆簼绨介柛鏃撶畱椤啴濡堕崱妤€娼戦梺绋款儐閹瑰洭寮诲☉銏″亹鐎规洖娲㈤埀顒佸笚娣囧﹪宕f径濠傤潓闂佸疇顫夐崹鍨暦閸洖鐓橀柣鎰靛墰娴滄瑩姊虹拠鏌ヮ€楃紒鐘茬Ч瀹曟洟宕¢悙宥嗙☉閳藉濮€閻橀潧濮︽俊鐐€栫敮鎺椝囬鐐村€堕柨鏃傜摂濞堜粙鏌i幇顒佲枙闁稿孩姊归〃銉╂倷閸欏鏋犲銈冨灪濡啫鐣烽妸鈺婃晣闁绘劙娼ч幖绋库攽閻樺灚鏆╅柛瀣█楠炴捇顢旈崱妤冪瓘闂佽鍨奸悘鎰洪鍕吅闂佺粯锚閸氣偓缂佹顦靛娲箰鎼达絿鐣甸梺鐟板槻椤戝鐣烽悽绋块唶婵犮埄浜濆Λ鍐极閸屾粎椹抽悗锝庝簻婵″ジ姊绘担鍛婃喐闁稿鍋ら獮鎰板箮閽樺鎽曢梺鍝勬储閸ㄥ綊鐛姀銈嗙厸闁搞儮鏅涘瓭婵犵鈧尙鐭欓柡宀嬬秮婵偓闁宠桨鑳舵禒鈺冪磽閸屾氨孝闁挎洦浜悰顔界節閸ャ劍娅㈤梺缁樓圭亸娆撴偪閳ь剚淇婇悙顏勨偓鏍箰妤e啫纾婚柣鏂挎憸椤╃兘鏌熼幍顔碱暭闁抽攱鍨块弻娑㈡晜鐠囨彃绗岄梺鑽ゅ枑閸f潙煤椤忓嫀褔鏌涢妷顔惧帥婵炶偐鍠栧娲礃閸欏鍎撻梺鐟板暱濮橈妇鎹㈠鑸碘拻濞达絽鎳欒ぐ鎺戝珘妞ゆ帒鍊婚惌娆撴煙閻戞﹩娈曢柛濠傜仛閵囧嫰寮崹顔规寖缂佺偓鍎抽妶鎼佸蓟閿熺姴绀冮柕濞垮劗閸嬫挾绮欓幐搴㈢槑濠电姷鏁告慨顓㈠箯閸愵喖绀嬮柛顭戝亞閺夊綊鏌f惔銏╁晱闁哥姵鐗犻幃銉╂偂鎼达絾娈惧┑顔姐仜閸嬫挸鈹戦埄鍐憙妞わ附濞婇弻娑㈠箻閺夋垹浠哥紓浣虹帛缁嬫捇鍩€椤掍胶鈯曞畝锝呮健閹本绻濋崑鑺ユ閹晠宕f径瀣瀾闂備浇妗ㄧ欢锟犲闯閿濆鈧線寮撮姀鈩冩珕闂佽姤锚椤︿粙鍩€椤掍胶鈽夐柍瑙勫灴閺佸秹宕熼锛勬崟濠电姭鎷冮崨顔界彧缂備緡鍠楅悷锔炬崲濠靛鐐婇柕濞у啫绠版繝鐢靛О閸ㄧ厧鈻斿☉銏℃櫇闁靛牆顦Ч鏌ユ煛閸モ晛鏋戦柛娆忕箻閺岋綁鎮㈤悡搴濆枈濠碘槅鍨崑鎾绘⒒娴h姤銆冪紒鈧担铏圭煋闁圭虎鍠楅崑鈺傜節闂堟侗鍎忕紒鈧崘鈹夸簻妞ゆ挾鍠庨悘锝夋煙鐎电ǹ鍘存慨濠勭帛閹峰懐绮电€n亝鐣伴梻浣告憸婵敻骞戦崶褏鏆︽繝闈涳功閻も偓濠电偞鍨兼ご鎼佸疾閿濆洨纾介柛灞剧懅閸斿秴鐣濋敐鍛仴闁糕斂鍨藉顕€宕奸悢鍝勫箺闂備胶鎳撻顓㈠磿閹寸偟鐟规繛鎴欏灪閻撴洟鏌¢崒姘变虎闁哄棴缍侀弻鈥崇暆鐎n剛鐦堥悗瑙勬礃鐢帡锝炲┑瀣垫晣闁绘﹢娼ч獮鈧紓鍌氬€搁崐鐑芥倿閿曞倶鈧啴宕ㄥ銈呮喘閺屽棗顓奸崨顖氬Е婵$偑鍊栫敮鎺楀窗濮橆兗缂氶柟閭﹀枤绾惧吋銇勯弮鍥т汗缂佺姴顭烽弻銊モ攽閸繀妲愰梺杞扮閸熸潙鐣烽幒鎴僵闁告鍋為幉銏ゆ⒒娴h棄鍚瑰┑鐐╁亾缂傚倸鍊归懝楣冨煝瀹ュ鏅查柛銉㈡櫇閻撳姊洪崜鑼帥闁哥姵鎹囬崺鈧い鎺嶇缁楁帗銇勯锝囩疄妞ゃ垺锕㈤幃鈺咁敃閿濆孩缍岄梻鍌氬€风欢姘缚瑜嶇叅闁靛牆鎮垮ú顏勎╅柍杞拌兌閸旓箑顪冮妶鍡楃瑨闁稿妫濆銊╂偋閸垻顔曟繝銏f硾椤戝洤煤鐎电硶鍋撶憴鍕8闁搞劏濮ゆ穱濠囧醇閺囩偟鍊為梺闈浨归崕鐑樺閺囥垺鐓熼柣鏂挎憸閻苯顭胯椤ㄥ牓寮鍢夋棃宕崘顏嗏棨濠电姰鍨奸崺鏍礉閺嶎厼纾婚柨婵嗩槹閻撴洟鏌曟径妯虹仩妞も晩鍓欓埥澶愬箻閻熸壆姣㈢紓浣介哺鐢岣胯箛娑樜╃憸蹇涙偩婵傚憡鈷戠憸鐗堝俯濡垵鈹戦悙鈺佷壕闂備浇顕栭崰妤冨垝閹捐绠板┑鐘插暙缁剁偛顭跨捄铏圭伇婵﹦鍋撶换婵嬫偨闂堟稐绮跺銈嗘处閸樹粙骞堥妸锔哄亝闁告劑鍔嶅Σ顒勬⒑閸濆嫮鈻夐柛妯恒偢瀹曞綊宕掗悙瀵稿帾婵犵數鍋熼崑鎾斥枍閸℃稒鐓曢悗锝冨妼婵″ジ妫佹径鎰叆婵犻潧妫欓崳褰掓煛閸℃瑥鏋戝ǎ鍥э躬椤㈡稑顫濋崡鐐╁徍婵犳鍠栭敃銉ヮ渻娴犲鈧線寮撮姀鈩冩珳闂佺硶鍓濋悷锕傤敇婵犳碍鈷掑ù锝堟鐢盯鏌熺喊鍗炰簽闁瑰箍鍨归埞鎴犫偓锝庡墮缁侊箓鏌f惔顖滅У闁哥姵鐗滅划濠氭晲閸℃瑧鐦堟繝鐢靛Т閸婃悂顢旈锔界厵闁哄鍋勬慨鍌涙叏婵犲啯銇濇鐐村姈閹棃鏁愰崒娑辨綌闂傚倷绀侀幖顐︽偋濠婂牆绀堥柣鏃堫棑閺嗭箓鏌i悢绋款棎闁割偒浜弻娑㈠即閵娿儱瀛e┑鐐存綑鐎氼剟鈥旈崘顔嘉ч柛鈩冾殘閻熸劙姊虹紒妯洪嚋缂佺姵鎸搁锝夊箮缁涘鏅滈梺鍓插亞閸犳捇宕㈤柆宥嗏拺闁荤喓澧楅幆鍫㈢磼婢跺缍戦柣锝囨暬瀹曞崬鈽夊▎鎴濆笚闁荤喐绮嶇划鎾崇暦濠婂喚娼╂い鎺戭槹閸嶇敻姊洪棃娴ュ牓寮插⿰鍫濈;闁稿瞼鍋為悡銉╂煟閺傛寧鎯堢€涙繈鏌i悢鍝ユ嚂缂佺姵鎹囬悰顕€寮介鐐殿啇濡炪倖鎸鹃崑鐔哥椤栨粎纾藉ù锝嗗絻娴滅偓绻濋姀锝嗙【闁愁垱娲濋妵鎰板箳閹寸媭妲梻浣呵圭换妤呭磻閹邦兘鏋旈柕鍫濐槹閳锋垹绱撴担璐細缂佺姵鐗犻弻锝夊煛婵犲倻浠╅梺浼欑悼閸忔﹢寮幘缁樺亹闁肩⒈鍓﹀Σ浼存⒒娴h棄浜归柍宄扮墦瀹曟粌顫濇0婵囨櫓闂佺鎻梽鍕煕閹达附鍋i柛銉岛閸嬫捇鎼归銈勭按闂傚倷绀侀幉锟犲蓟閵婏富娈介柟闂寸閻撴繈鏌熼幑鎰靛殭缂佺媴缍侀弻锝夊箛椤撶喓绋囧銈呭閹告悂鍩為幋锔藉亹閻犲泧鍐х矗闂備礁鎽滈崳銉╁垂閸洜宓侀柛鈩冪☉绾惧吋鎱ㄩ敐搴″箹缂傚秴锕獮鍐煛閸涱厾顔岄梺鍦劋缁诲倹淇婇柨瀣瘈闁汇垽娼цⅴ闂佺ǹ顑嗛幑鍥蓟閻斿皝鏋旈柛顭戝枟閻忔挾绱掓ィ鍐暫缂佺姵鐗犲濠氭偄鐞涒€充壕闁汇垻娅ラ悷鐗堟瘎闂佽崵鍠愮划搴㈡櫠濡ゅ懏鍋傞柨鐔哄Т閽冪喐绻涢幋娆忕仼缂佺姵濞婇弻锟犲磼濮樿鲸鐨戦梺鍝勵儏閹冲酣鍩為幋锔藉€烽柛娆忣槸濞咃綁姊绘担绋跨盎缂佽尙鍋撶粚杈ㄧ節閸パ咁啋濡炪倖妫佹慨銈呪枍閵忋倖鈷戦悹鎭掑妼濞呮劙鏌熼崙銈嗗Department of Medicine, University of California, San Francisco, California 94118
Department of Surgery, University of California, San Francisco, California 94143
Grifols Biologicals, Los Angeles, California 90032
ABSTRACT
The full protein coding region of human immunodeficiency virus (HIV) genomes were sequenced using plasma collected from nine African-Americans prior to seroconversion and 7 to 28 days later. HIV mutations emerged in seven of these subjects at a genomewide rate of 2% per year. The location of nonsynonymous (NS) HIV mutations within these subjects was compared to their potential HLA-A and B types restricted CTL epitopes reported in the Los Alamos National Laboratory HIV immunology database. A statistically significant (P < 0.005) number of the early NS mutations (13.5%) were found within previously reported CTL epitopes. A virus sequencing and reported CTL epitopes database analysis therefore support a model where a significant proportion of very early nonsynonymous HIV mutations are selected by CTL.
TEXT
Cytotoxic T-lymphocytes (CTL) play an important role in controlling viremia during primary human immunodeficiency virus (HIV) infection (6, 29). CTL recognize viral peptides presented in a complex with HLA class I molecules at the surface of infected cells, inducing T-cell activation and clonal expansions followed by lysis of infected target cells (37, 40). The resulting selection pressure on the replicating virus can lead to the emergence of CTL escape variants (7, 9, 18-20, 22, 25, 26, 36). CTL targeted epitopes have been reported in every HIV protein in the Los Alamos Database (28). The breadth of HIV-1-specific CTL response increases during chronic versus primary infection (4, 8, 13, 19). CTL responses appear to favor epitopes within regulatory and accessory proteins during primary infection, whereas later responses appear to preferentially recognize structural proteins (1, 8, 9).
CTL escape has been powerfully illustrated by the identification of an immunodominant Mamu-A01-restricted Tat-specific CTL response rapidly selecting for viral escape variants during acute simian immunodeficiency virus (SIV) infection (3, 32). In the SIV model system, peptide reagents of the infecting SIV strain have allowed all CTL epitopes restricted by various HLA class I allele to be identified. As many as 64% of NS mutations selected over the entire course of SIV infection outside of the envelope gene have been located with known CTL epitopes (33). In HIV-1-infected subjects, viral mutations preventing CTL recognition were described in immunodominant epitopes and were correlated with a steady rise in viral load and disease progression (18, 25).
On a population basis, Moore et al. compared HIV protease and reverse transcriptase sequences of chronically infected patients to their presumably ancestral subtype consensus sequence and showed that consensus deviating sequences were overrepresented in known HLA-restricted CTL epitopes (31). When phylogenetically closely related but epidemiologically unlinked HIV genomes were analyzed positive selection in potential CTL target sites was also detected (35). Particular HLA types have also been associated with susceptibility or resistance to HIV infection (14, 30, 38) as well as with slow or rapid disease progression (10, 11, 16, 17, 21, 23, 24, 39).
To directly identify HIV sequence changes and characterize HIV-1 regions undergoing possible selection very early following infection, we sequenced plasma HIV genomes of nine African-American plasma donors at two time points (Fig. 1). Subjects reported no symptoms of acute infection at the time of plasma collection and were not febrile. The initial donations were p24 antigen negative, anti-HIV-1 antibody negative, and HIV-1 RNA negative (using the National Genetics Institute UltraQual HIV-1 reverse transcription-PCR assay with a detection limit of five HIV-1 genome copies/ml) except for subjects 1057 and PRB959, who had an initial plasma viremia of 3.9 x 104 and 2 x 105 HIV-1 RNA copies/ml, respectively (Fig. 1). Longitudinally collected plasma samples were then quantified with the NGI SuperQuant HIV-1 reverse transcription-PCR assay. Anti-HIV antibodies were detected using the HIV-1 enzyme immunoassay (Abbott, Abbott Park, IL) and p24 antigenemia was detected with the Coulter HIV-1 p24 antigen assay (Beckman Coulter, Brea, CA) (Fig. 1). Antiretroviral therapies were not initiated during the period of study. Because donations were of plasma only, no peripheral blood mononuclear cells were available for functional analyses of the CTL response. These studies were approved by the University of California, San Francisco Committee on Human Research.
Seroconversion was observed during the second or third week following initial RNA detection for seven subjects, during week 1 for 1001, and during the fourth week for 1057. The initial plasma donations of subject 1057 and PRB959 were already viremic but subsequent seroconversion confirmed primary infection status.
All open reading frames of plasma HIV-1 RNA from two time points separated by 7 to 28 days (arrows in Fig. 1) were sequenced. For genome amplification plasma HIV-1 RNA was purified, reverse transcribed, and subjected to nested PCR (5). The resulting half-genome amplicons were directly sequenced. The PCR and sequencing protocols have been described in detail (5). Sequences were manually edited using EditView, assembled into a single contig, and aligned using the Seqman and Megalign programs, respectively (DNAstar Inc., Madison, WI). The wide variation in the location of HIV mutations evolving within each subject is shown in Fig. 2.
Both complete and partial nucleotide sequence changes were observed by direct amplicon sequencing. Partial nucleotide changes were detected when either time point showed a mixed base consisting of two overlapping sequencing electrophoregram peaks (where the minority peak reached 25% of the dominant peak) while the other time point showed only a single base peak. These mixed bases are recorded using the IUB nomenclature in the deposited sequences (GenBank accession numbers AY331282 to AY331297, AY332236, and AY332237). Mixed bases, commonly seen when directly sequencing HIV amplicons, reflect polymorphisms in the viral quasispecies that are not yet fixed in the entire viral population. The short time interval between sampled plasma pairs is likely responsible for the frequent detection of such partial nucleotide changes. Partial mutations were analyzed in the same way as full nucleotide substitutions (i.e., positions changing from single into mixed residues, and vice versa, were counted as one mutation). No codon contained more than a single mixed base, and therefore all codons with a mixed base could be translated into only one or two amino acids.
No mutations were observed in subjects 1006 and 1027, who were sampled only 7 and 12 days apart (Fig. 1). For the seven other genome pairs, a total of 107 nucleotide substitutions were detected, resulting in intrasubject mutation frequencies of 0.08% to 0.37%. The accumulation of nucleotide substitutions occurred at an average yearly rate of 2.05%. The genomewide dN/dS ratios, calculated using the SNAP program from the HIV sequence database [www.hiv.lanl.gov (27)], ranged from 0.249 to 0.87, reflecting overall purifying selection against amino acid changes. The gene distribution of NS mutations varied widely between donors. Overall the highest number of NS mutations was located in env (n = 19), pol (n = 15), gag (n = 14), nef (n = 6), vif (n = 3), and vpr (n = 3). In these subjects no NS mutations were detected in the early expressed accessory genes tat, rev, and vpu. When adjusted for gene length, the highest density of NS mutations was found with the vpr, nef, and gag genes (The high mutation rate for the short open reading frame of vpr was the result of a single NS mutation in three subjects [1013, 1018, and 1057] located within Vpr amino acids 34 to 40).
The total number of nucleotide substitutions was correlated with both the time interval between the two sequenced time points and the time interval between the initial detection of HIV RNA and the second sequenced time point (P = 0.05, r2 = 0.32 and P = 0.02, r2 = 0.48, respectively). The number of nucleotide substitutions was also positively correlated with changes in plasma viremia between the two sequenced time points (P = 0.04, r2 = 0.37) indicating that increasing viral loads were associated with a higher number of mutations. Similar trends were observed using NS mutations only (P = 0.09, r2 = 0.24; P = 0.006, r2 = 0.62; and P = 0.06, r2 = 0.3, respectively).
HIV-1 evolution is influenced by numerous virus-host interactions including changes in antibody and CTL selection pressures upon infection of a new host. In order to evaluate the influence of the HLA class I types on the location of early NS mutations, high-resolution HLA-A and -B types were determined by PCR and sequencing of human DNA purified from plasma samples. DNA was isolated in a clean room designed for pre-PCR manipulation using the QIAamp DNA mini kit (QIAGEN, Valencia, CA). Locus-specific PCR amplifications were performed for exons 2 and 3; exon 4 was amplified as required to resolve ambiguities (Perkin Elmer Life Sciences, Shelton, CT) (L. A. Baxter-Lowe, unpublished). Ambiguities involving polymorphism in the leader peptide (HLA-A7401/02 and B2705/13) were not resolved, because these mutations are not predicted to alter the peptide binding characteristics of the protein product. These are listed in Table 1 as HLA-A7401 and HLA-B2705. For subject 1013, there was insufficient DNA to resolve the exon 4 ambiguity of HLA-A2301/07N. This has been listed in Table 1 as HLA-A2301 as HLA-A2307N is extremely rare. Eighteen different HLA-A and -B types were detected among the seven plasma donors whose HIV evolved between the sampled time points (Table 1). Many of these types are frequently observed in African-Americans (10).
When published CTL epitopes for these 18 HLA class I molecules were sought in the existing literature only 13 of 18 HLA types had any CTL epitopes described (Los Alamos HIV immunology database, January 2005). A total of 62 HIV CTL epitopes with a range of 1 to 16 underlined epitopes per HLA type were identified. Eight of the 59 HIV NS mutations (13.5%) were located within reported HLA class I restricted epitopes (Table 2). These eight NS mutations, found in three subjects, were within epitopes restricted by one or in two cases by two of their host's class I molecules (Table 2).
We calculated the probability of 8 out of 59 NS mutations occurring within previously reported CTL epitopes for the seven subjects with HIV mutations. All 62 reported epitopes restricted by their hosts' class I HLA-A and HLA-B molecules were compiled from the database. The total numbers of amino acids included within reported CTL epitopes were calculated individually for each of the seven primary infection subjects and then added up (the same amino acids found in overlapping epitopes within the same subject were counted once). A total of 943 amino acids were found within reported CTL epitopes. The total number of amino acids encoded by HIV in these seven subjects was 22,048 (Table 3). The fraction of virally encoded amino acids within reported CTL epitopes was therefore 943/22,048 (4.3%). The proportion of NS mutations found within these reported CTL epitopes was 8/59 (13%), which was significantly greater than expected by chance, considering the low density (4.3%) of reported CTL epitopes (P < 0.005, test of proportion and Fisher’s exact test). This result indicated that NS mutations evolving within the first month of infection were significantly more likely to be found within than outside a reported CTL epitope.
We also calculated separately for each subject and for all subjects together the odds ratio of finding an NS mutation in a predicted CTL epitope (Table 3). Odds ratio values in three subjects were greater than one, ranging from 3.9 to 5.7, reflecting the preferential location of NS mutations within reported CTL epitopes. An odds ratio of 3.1 was calculated using all seven subjects with HIV mutations.
The number of CTL epitopes restricted by the HLA class I molecules of these African American plasma donors in the Los Alamos databases is likely to be a large underestimate of potential epitopes, because many of these HLA types have not been studied in detail (i.e., no CTL epitopes were reported for 5 of the 18 HLA types). Furthermore most studies mapping epitopes have done so using only a subset of HIV proteins, and epitopes have typically been identified using reference or subtype consensus strains rather than autologous strains. Mutational escape from CTL can also occur at different steps during peptide processing and HLA binding. Viral protein degradation by the proteasome, transport of peptides into the endoplasmic reticulum, peptide trimming, and peptide loading may all be affected by sequence changes flanking rather than within the final antigenic peptide (2, 12, 15). Finally, some NS mutations linearly distant from the CTL epitope may also be selected as compensatory mutations to reduce the fitness cost imposed by CTL escape mutations (34).
The immature state of the immune response so early following primary infection may also have limited the amount of CTL selection pressure on the replicating quasispecies although in the SIV model system immunodominant epitope escape mutations have been seen within 4 weeks of infection (3, 32). The percentage of early NS mutations reported here that may affect CTL epitopes may therefore be a minimum value. Indeed we noted that the two subjects with the highest number of HLA-A and -B types restricted CTL epitopes in the database (1001 and 1057) were among the three subjects with an overabundance of NS mutations within reported epitopes (Tables 2 and 3). As more CTL epitopes to less frequent HLA-A and -B types are reported, a greater proportion of very early NS mutations may therefore be found within CTL epitopes.
In summary, the location of NS mutations occurring within the first month of acute HIV infection varied greatly among subjects. The influence of the host's class I HLA type was reflected within weeks of infection by the preferential distribution of 13.5% of NS mutations within previously reported CTL epitopes.
ACKNOWLEDGMENTS
Support for this study was provided to E.L.D. by the UC Universitywide AIDS Research Program (ID02-SF-075) and NIAID (AI47320 and AI43261).
REFERENCES
Addo, M. M., M. Altfeld, E. S. Rosenberg, R. L. Eldridge, M. N. Philips, K. Habeeb, A. Khatri, C. Brander, G. K. Robbins, G. P. Mazzara, P. J. Goulder, and B. D. Walker. 2001. The HIV-1 regulatory proteins Tat and Rev. are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. USA 98:1781-1786.
Allen, T. M., M. Altfeld, X. G. Yu, K. M. O'Sullivan, M. Lichterfeld, S. Le Gall, M. John, B. R. Mothe, P. K. Lee, E. T. Kalife, D. E. Cohen, K. A. Freedberg, D. A. Strick, M. N. Johnston, A. Sette, E. S. Rosenberg, S. A. Mallal, P. J. Goulder, C. Brander, and B. D. Walker. 2004. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78:7069-7078.
Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386-390.
Altfeld, M., E. S. Rosenberg, R. Shankarappa, J. S. Mukherjee, F. M. Hecht, R. L. Eldridge, M. M. Addo, S. H. Poon, M. N. Phillips, G. K. Robbins, P. E. Sax, S. Boswell, J. O. Kahn, C. Brander, P. J. Goulder, J. A. Levy, J. I. Mullins, and B. D. Walker. 2001. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193:169-180.
Bernardin, F., B. L. Herring, L. Peddada, and E. L. Delwart. 2003. Primary infection of a male plasma donor with divergent HIV variants from the same source followed by rapid fluctuations in their relative frequency and viral recombination. AIDS Res. Hum. Retroviruses 19:1009-1015.
Borrow, P., H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. Oldstone. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
Cao, J., J. McNevin, S. Holte, L. Fink, L. Corey, and M. J. McElrath. 2003. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J. Virol. 77:6867-6878.
Cao, J., J. McNevin, U. Malhotra, and M. J. McElrath. 2003. Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J. Immunol. 171:3837-3846.
Carrington, M., and R. E. Bontrop. 2002. Effects of MHC class I on HIV/SIV disease in primates. AIDS 16(Suppl. 4):S105-114.
Carrington, M., G. W. Nelson, M. P. Martin, T. Kissner, D. Vlahov, J. J. Goedert, R. Kaslow, S. Buchbinder, K. Hoots, and S. J. O'Brien. 1999. HLA and HIV-1: heterozygote advantage and B35-Cw04 disadvantage. Science 283:1748-1752.
Craiu, A., T. Akopian, A. Goldberg, and K. L. Rock. 1997. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc. Natl. Acad. Sci. USA 94:10850-10855.
Dalod, M., M. Dupuis, J. C. Deschemin, C. Goujard, C. Deveau, L. Meyer, N. Ngo, C. Rouzioux, J. G. Guillet, J. F. Delfraissy, M. Sinet, and A. Venet. 1999. Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J. Clin. Investig. 104:1431-1439.
de Sorrentino, A. H., K. Marinic, P. Motta, A. Sorrentino, R. Lopez, and E. Illiovich. 2000. HLA class I alleles associated with susceptibility or resistance to human immunodeficiency virus type 1 infection among a population in Chaco Province, Argentina. J. Infect. Dis. 182:1523-1526.
Draenert, R., S. Le Gall, K. J. Pfafferott, A. J. Leslie, P. Chetty, C. Brander, E. C. Holmes, S. C. Chang, M. E. Feeney, M. M. Addo, L. Ruiz, D. Ramduth, P. Jeena, M. Altfeld, S. Thomas, Y. Tang, C. L. Verrill, C. Dixon, J. G. Prado, P. Kiepiela, J. Martinez-Picado, B. D. Walker, and P. J. Goulder. 2004. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J. Exp. Med. 199:905-915.
Gao, X., G. W. Nelson, P. Karacki, M. P. Martin, J. Phair, R. Kaslow, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, S. J. O'Brien, and M. Carrington. 2001. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344:1668-1675.
Geczy, A. F., H. Kuipers, M. Coolen, L. J. Ashton, C. Kennedy, G. Ng, R. Dodd, R. Wallace, T. Le, C. H. Raynes-Greenow, W. B. Dyer, J. C. Learmont, and J. S. Sullivan. 2000. HLA and other host factors in transfusion-acquired HIV-1 infection. Hum. Immunol. 61:172-176.
Geels, M. J., M. Cornelissen, H. Schuitemaker, K. Anderson, D. Kwa, J. Maas, J. T. Dekker, E. Baan, F. Zorgdrager, R. van den Burg, M. van Beelen, V. V. Lukashov, T. M. Fu, W. A. Paxton, L. van der Hoek, S. A. Dubey, J. W. Shiver, and J. Goudsmit. 2003. Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J. Virol. 77:12430-12440.
Goulder, P. J., C. Brander, Y. Tang, C. Tremblay, R. A. Colbert, M. M. Addo, E. S. Rosenberg, T. Nguyen, R. Allen, A. Trocha, M. Altfeld, S. He, M. Bunce, R. Funkhouser, S. I. Pelton, S. K. Burchett, K. McIntosh, B. T. Korber, and B. D. Walker. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412:334-338.
Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-217.
Hendel, H., S. Caillat-Zucman, H. Lebuanec, M. Carrington, S. O'Brien, J. M. Andrieu, F. Schachter, D. Zagury, J. Rappaport, C. Winkler, G. W. Nelson, and J. F. Zagury. 1999. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 162:6942-6946.
Jones, N. A., X. Wei, D. R. Flower, M. Wong, F. Michor, M. S. Saag, B. H. Hahn, M. A. Nowak, G. M. Shaw, and P. Borrow. 2004. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J. Exp. Med. 200:1243-1256.
Kaslow, R. A., M. Carrington, R. Apple, L. Park, A. Munoz, A. J. Saah, J. J. Goedert, C. Winkler, S. J. O'Brien, C. Rinaldo, R. Detels, W. Blattner, J. Phair, H. Erlich, and D. L. Mann. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-411.
Keet, I. P., J. Tang, M. R. Klein, S. LeBlanc, C. Enger, C. Rivers, R. J. Apple, D. Mann, J. J. Goedert, F. Miedema, and R. A. Kaslow. 1999. Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. J. Infect. Dis. 180:299-309.
Kelleher, A. D., C. Long, E. C. Holmes, R. L. Allen, J. Wilson, C. Conlon, C. Workman, S. Shaunak, K. Olson, P. Goulder, C. Brander, G. Ogg, J. S. Sullivan, W. Dyer, I. Jones, A. J. McMichael, S. Rowland-Jones, and R. E. Phillips. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375-386.
Koenig, S., A. J. Conley, Y. A. Brewah, G. M. Jones, S. Leath, L. J. Boots, V. Davey, G. Pantaleo, J. F. Demarest, C. Carter, et al. 1995. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1:330-336.
Korber, B. HIV signature and sequence variation analysis, p. 55-72. In A. G. Rodrigo and G. H. Learn (ed.), Computational analysis of HIV molecular sequences. Kluwer Academic Publishers, Dordrecht, The Netherlands.
Korber, B. T. M., C. Brander, B. F. Haynes, R. A. Koup, C. Kuiken, J. P. Moore, B. D. Walker, and D. I. Watkins. 2002. HIV molecular immunology, LA-UR 03-5816 ed. Los Alamos National Library Theoretical Biology and Physics, Los Alamos, N.Mex.
Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
MacDonald, K. S., K. R. Fowke, J. Kimani, V. A. Dunand, N. J. Nagelkerke, T. B. Ball, J. Oyugi, E. Njagi, L. K. Gaur, R. C. Brunham, J. Wade, M. A. Luscher, P. Krausa, S. Rowland-Jones, E. Ngugi, J. J. Bwayo, and F. A. Plummer. 2000. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:1581-1589.
Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439-1443.
O'Connor, D. H., T. M. Allen, T. U. Vogel, P. Jing, I. P. DeSouza, E. Dodds, E. J. Dunphy, C. Melsaether, B. Mothe, H. Yamamoto, H. Horton, N. Wilson, A. L. Hughes, and D. I. Watkins. 2002. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:493-499.
O'Connor, D. H., A. B. McDermott, K. C. Krebs, E. J. Dodds, J. E. Miller, E. J. Gonzalez, T. J. Jacoby, L. Yant, H. Piontkivska, R. Pantophlet, D. R. Burton, W. M. Rehrauer, N. Wilson, A. L. Hughes, and D. I. Watkins. 2004. A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J. Virol. 78:14012-14022.
Peyerl, F. W., D. H. Barouch, W. W. Yeh, H. S. Bazick, J. Kunstman, K. J. Kunstman, S. M. Wolinsky, and N. L. Letvin. 2003. Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J. Virol. 77:12572-12578.
Piontkivska, H., and A. L. Hughes. 2004. Between-host evolution of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1: an approach based on phylogenetically independent comparisons. J. Virol. 78:11758-11765.
Price, D. A., P. J. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. Troop, C. R. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94:1890-1895.
Rammensee, H. G., J. Bachman, and S. Stevanovich. 1997. MHC ligands and peptide motifs. Landes Biosciences., Georgetown, Texas.
Rowland-Jones, S. L., T. Dong, K. R. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyoshi, J. Oyugi, E. Ngugi, J. Bwayo, K. S. MacDonald, A. J. McMichael, and F. A. Plummer. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Investig. 102:1758-1765.
Tang, J., C. Costello, I. P. Keet, C. Rivers, S. Leblanc, E. Karita, S. Allen, and R. A. Kaslow. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 15:317-324.
Zinkernagel, R. M., and P. C. Doherty. 1979. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27:51-177.(Flavien Bernardin, Denice)